¿Cómo se compara el ratio PE de 0TDF con empresas similares?

0TDF es un buen valor basado en su ratio Price-To-Earnings (19x) comparado con la media de empresas similares (22.6x).

¿Cómo se compara el ratio PE de 0TDF con el de otras empresas de la industria European Pharmaceuticals ?

0TDF es un buen valor basado en su ratio Price-To-Earnings (19x) comparado con la media de la industria UK Pharmaceuticals (31.4x).

¿Cuál es el ratio PE de 0TDF comparado con su ratio PE justo? Este es el ratio PE esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

0TDF es un buen valor basado en su ratio Price-To-Earnings (19x) comparado con el ratio justo estimado Price-To-Earnings (37x).

¿Cuál es el precio justo de 0TDF si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

0TDF ($35.55) cotiza por debajo de nuestra estimación de [[valor justo]] ($101.87)

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

Datos insuficientes para mostrar el pronóstico de precios.

Roche Holding (LSE:0TDF) - Cotización, noticias y análisis

Resumen de acción 0TDF

Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Oceanía. Saber más

Análisis fundamental de 0TDF
Puntuación del snowflake
Valoración	5/6
Crecimiento futuro	3/6
Rendimiento pasado	0/6
Salud financiera	3/6
Dividendos	5/6

Recompensas

Cotiza un 65.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 11.15%

Paga dividendo fiable de 3.79%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Tiene un alto nivel de endeudamiento

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de Roche Holding AG

AstraZeneca

LSE:AZN

UK£162.4b

GSK

LSE:GSK

UK£54.9b

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

Novartis

SWX:NOVN

CHF 183.8b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Roche Holding
Precios históricos de las acciones
Precio actual de la acción	CHF 35.55
Máximo en las últimas 52 semanas	CHF 41.85
Mínimo de 52 semanas	CHF 29.27
Beta	0.15
1Cambio en 1 mes	-12.40%
Variación en 3 meses	-15.05%
Cambio de 1 año	5.49%
3Variación en 3 años	-27.20%
Variación en 5 años	-6.89%
Variación desde la OPV	15.09%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0TDF	GB Pharmaceuticals	Mercado GB
7D	0.4%	5.0%	2.2%
1Y	5.5%	2.5%	8.8%

Rentabilidad vs. Industria: 0TDF superó a la industria UK Pharmaceuticals, que obtuvo un rendimiento del 2.5% el año pasado.

Rentabilidad vs. Mercado: 0TDF obtuvo unos resultados inferiores a los del mercado UK, que fueron del 8.8% el año pasado.

Volatilidad de los precios

Is 0TDF's price volatile compared to industry and market?
0TDF volatility
0TDF Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0TDF no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0TDF (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Oceanía. La empresa ofrece productos farmacéuticos en las áreas terapéuticas de anemia, tumores sanguíneos y sólidos, dermatología, hemofilia, enfermedades inflamatorias y autoinmunes, trastornos neurológicos, oftalmología, trastornos respiratorios y trasplantes. También está desarrollando productos para diversas áreas terapéuticas.

Resumen de fundamentos de Roche Holding AG

¿Cómo se comparan los beneficios e ingresos de Roche Holding con su capitalización de mercado?
Estadísticas fundamentales de 0TDF
Capitalización bursátil	US$230.29b
Beneficios(TTM)	US$11.98b
Ingresos (TTM)	US$68.36b

19.0x

Ratio precio-beneficio (PE)

3.3x

Ratio precio-ventas (PS)

¿Está 0TDF sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0TDF
Ingresos	CHF 60.58b
Coste de los ingresos	CHF 15.43b
Beneficio bruto	CHF 45.16b
Otros gastos	CHF 34.54b
Beneficios	CHF 10.62b

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	13.33
Margen bruto	74.54%
Margen de beneficio neto	17.53%
Ratio deuda/patrimonio	104.8%

¿Cómo se ha desempeñado 0TDF a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.8%

Rentabilidad actual por dividendo

72%

Ratio de pagos

Resumen de acción 0TDF

Recompensas

Análisis de riesgos

Competidores de Roche Holding AG

LSE:AZN

UK£162.4b

LSE:GSK

UK£54.9b

LSE:HIK

UK£4.4b

SWX:NOVN

CHF 183.8b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Recent updates

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran